# Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation

**Authors:** Anne Marchalot, Malin Ljunggren, Christopher Stamper, Whitney Weigel, Christopher Andrew Tibbitt, Isabel Meininger, Ram Vinay Pandey, Miriam Franklin, John Washington Bassett, Lorenz Wirth, Ali Kiasat, Ali Kiasat, Anders Hansson Elliot, Carl Kördel, Emma Rosander, Henrik Iversen, Madelene Ahlberg, Mirna Abraham-Nordling, Petri Rantanen, Richard Marsk, Stefan Carlens, Ulf O. Gustafsson, Ulrik Lindforss, Gabriella Jansson-Palmer, Caroline Nordenvall, Jenny Mjösberg

PMC · DOI: 10.1038/s41467-026-71085-9 · 2026-03-27

## TL;DR

This study explores immune cell changes in colorectal cancer and peritoneal metastases, finding increased ILC1 and tissue-resident NK cells.

## Contribution

The study identifies immature innate lymphoid cells biased toward ILC1 and tissue-resident NK cell differentiation in CRC and PM.

## Key findings

- CRC and CRC-PM tumors are depleted of ILC3 but enriched for ILC1, trNK, and cNK cells.
- Two immature ILC populations in tumors show a transcriptional bias toward ILC1 and trNK cells.
- nILCs differentiate into ILC1/trNK-like cells when co-cultured with OP9-DL1 cells.

## Abstract

Peritoneal metastases (PM) occur in 10% of patients with colorectal cancer (CRC) and are linked to poor outcomes. Although dysregulated innate lymphoid cells (ILC) have been described in CRC, their function in CRC-PM remains unclear. Here, we analyze tumor samples from CRC and CRC-PM patients using single-cell RNA sequencing (11 patients), flow cytometry (8 patients) and differentiation assays (24 patients). Healthy colon, primary CRC and CRC-PM tumors are infiltrated by heterogeneous populations of ILC3, ILC2, ILC1, tissue resident (tr)NK cells and conventional (c)NK cells. Compared to healthy colons, primary CRC and CRC-PM tumors are depleted of ILC3 but enriched for ILC1, trNK cells and cNK cells. CRC and CRC-PM tumors harbor two immature ILC populations, early NK and naïve (n)ILC, with nILCs being transcriptionally skewed toward ILC1 and trNK cells. Indeed, co-culture of isolated nILCs with OP9-DL1 cells induces intratumoral nILC differentiation into ILC1/trNK-like cells. These findings help understand the immune pathogenesis of CRC and CRC-PM and provide insights for future ILC1 and NK cell-based therapies.

Patients with colorectal cancer (CRC) may develop peritoneal metastases (PM), but information on the immune niche is still lacking. Here, the authors analyze primary tumor and metastasis samples to reveal a skewed innate lymphoid cell balance marked by an increase in ILC1/tissue-resident NK cells.

## Linked entities

- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** Itgae (integrin alpha E, epithelial-associated) [NCBI Gene 16407] {aka A530055J10, CD103, aM290, alpha-E1, alpha-M290}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, Cd160 (CD160 antigen) [NCBI Gene 54215] {aka By55}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, TIPARP (TCDD inducible poly(ADP-ribose) polymerase) [NCBI Gene 25976] {aka ARTD14, PARP7, pART14}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, DLL1 (delta like canonical Notch ligand 1) [NCBI Gene 28514] {aka DELTA1, DL1, Delta, NEDBAS}, TRNK (tRNA-Lys) [NCBI Gene 4566] {aka MTTK}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577] {aka C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}, RGS2 (regulator of G protein signaling 2) [NCBI Gene 5997] {aka G0S8}, PTGDR2 (prostaglandin D2 receptor 2) [NCBI Gene 11251] {aka CD294, CRTH2, DL1R, DP2, GPR44}, XCL2 (X-C motif chemokine ligand 2) [NCBI Gene 6846] {aka SCM-1b, SCM1B, SCYC2}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, MZB1 (marginal zone B and B1 cell specific protein) [NCBI Gene 51237] {aka MEDA-7, PACAP, pERp1}, CD3E (CD3 epsilon subunit of T-cell receptor complex) [NCBI Gene 916] {aka CD3epsilon, IMD18, T3E, TCRE}, XCL1 (X-C motif chemokine ligand 1) [NCBI Gene 6375] {aka ATAC, LPTN, LTN, SCM-1, SCM-1a, SCM1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, Eomes (eomesodermin) [NCBI Gene 13813] {aka TBR-2, Tbr2}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, IL10RA (interleukin 10 receptor subunit alpha) [NCBI Gene 3587] {aka CD210, CD210a, CDW210A, HIL-10R, IL-10R1, IL10R}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, GZMK (granzyme K) [NCBI Gene 3003] {aka GrK, TRYP2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CD3D (CD3 delta subunit of T-cell receptor complex) [NCBI Gene 915] {aka CD3-DELTA, CD3DELTA, IMD19, T3D}, KLRF1 (killer cell lectin like receptor F1) [NCBI Gene 51348] {aka CLEC5C, NKp80}, PTGER4 (prostaglandin E receptor 4) [NCBI Gene 5734] {aka EP4, EP4R}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, Il23a (interleukin 23, alpha subunit p19) [NCBI Gene 83430] {aka IL-23, p19}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, Fcgr3 (Fc receptor, IgG, low affinity III) [NCBI Gene 14131] {aka CD16}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, NCR2 (natural cytotoxicity triggering receptor 2) [NCBI Gene 9436] {aka CD336, LY95, NK-p44, NKP44, dJ149M18.1}, Atp7a (ATPase, copper transporting, alpha polypeptide) [NCBI Gene 11977] {aka MNK}, GEM (GTP binding protein overexpressed in skeletal muscle) [NCBI Gene 2669] {aka KIR}, ITGA1 (integrin subunit alpha 1) [NCBI Gene 3672] {aka CD49a, VLA1}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, ITGAE (integrin subunit alpha E) [NCBI Gene 3682] {aka CD103, HUMINAE}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, KLRB1 (killer cell lectin like receptor B1) [NCBI Gene 3820] {aka CD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, CD1D (CD1d molecule) [NCBI Gene 912] {aka R3, R3G1}
- **Diseases:** hematological malignancies (MESH:D019337), type 2 inflammation (MESH:D007249), Colon (MESH:D003108), Tumor-Node-Metastasis (MESH:D008207), breast, bladder, head and neck, and lung cancer (MESH:D001943), colon tumor (MESH:D003110), PM tumors (MESH:D010534), Tumor (MESH:D009369), ILC (MESH:D016399), head and neck cancer (MESH:D006258), Colorectal cancer (MESH:D015179), cytotoxic (MESH:D064420), death (MESH:D003643), PM (MESH:D010538), metastases (MESH:D009362), skin infection (MESH:D007239)
- **Chemicals:** nitrogen (MESH:D009584), PBS (MESH:D007854), DMSO (MESH:D004121), ionomycin (MESH:D015759), PMA (MESH:D013755), paraformaldehyde (MESH:C003043), DA (-)
- **Species:** Mycoplasma (genus) [taxon 2093], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** NK92 — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_2142), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), OP9 — Mus musculus (Mouse), Stromal cell line (CVCL_4398), OP9-DL1 — Mus musculus (Mouse), Stromal cell line (CVCL_B218), ILC — Homo sapiens (Human), Intellectual developmental disorder, Transformed cell line (CVCL_A7SR)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035902/full.md

---
Source: https://tomesphere.com/paper/PMC13035902